Slingshot members are tracking this event:
Halozyme Therapeutics (HALO) to commence Phase 1b/2 open label trial—under MORPHEUS platform—on PEG PH20, testing six tumors, including gastrointestinal, in 2017
Slingshot Insights Explained
Jul 13, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Morpheus, Gastrointestinal Cancer, Tumors, Pegph20, Phase 1b/2